Swiss pharma at risk of US trade investigation, industry body says

• The U.S. initiated a Section 301 investigation against Germany after it announced plans in April to overhaul its healthcare system and lower pharmaceutical spending
• Republican congressmen sent a letter urging investigations into Switzerland and Germany, accusing them of 'free-riding' off U.S. pharmaceutical innovation through pricing controls
• Pharmaceutical and chemical products comprised over half of Switzerland's exports last year, with major drugmakers Roche and Novartis headquartered there

Summary: Swiss Pharma Faces Potential US Trade Investigation

Switzerland's pharmaceutical industry may face a US Section 301 trade investigation similar to one recently launched against Germany, according to Interpharma CEO René Buholzer. The warning comes as Washington investigates suspected unfair trade practices across dozens of countries.

Key Development:

The US initiated an investigation into Germany last week after Berlin announced plans in April to overhaul its healthcare system and reduce pharmaceutical spending. Though the US could impose tariffs on German imports, sources indicate the government may be reconsidering following industry opposition.

Switzerland's Exposure:

Switzerland is currently reviewing measures to lower mandatory healthcare prices, including drug costs—a move the pharmaceutical industry opposes. Buholzer stated Switzerland is "a potential target" given its healthcare insurance ordinance revision.

Republican US lawmakers sent a letter this month urging the US Trade Representative and Commerce Secretary to investigate foreign pharmaceutical pricing policies, specifically naming both Germany and Switzerland as "free-riding" off US consumers. The lawmakers argue that foreign government spending curbs unfairly shift pharmaceutical innovation costs to American consumers.

Market Significance:

The stakes are substantial for Switzerland: pharmaceutical and chemical products accounted for over half of the country's exports last year. Major drugmakers Roche and Novartis are headquartered in Switzerland, making the sector critical to the national economy.

Bottom Line:

A potential US trade investigation could result in tariffs affecting Swiss pharmaceutical exports, threatening a sector that dominates the country's trade profile. Investors should monitor developments in Swiss healthcare pricing reforms and US trade policy responses.